Isomorphic Labs, an AI drug discovery platform spun from Google's Deepmind in 2021, raised external capital for the first time. The $600 million round was led by Thrive Capital, with participation from GV's parent and existing investor Alphabet.
The funding will accelerate further development of Isomorphic's AI drug design engine and support the company's goal of bringing discovered drugs into clinical trials.
The isomorphic lab was founded by DeepMind co-founder Demis Hassabis by leveraging DeepMind's software for AI drug discovery, including AI models that predict the three-dimensional structure of proteins.
Last year, Isomorphic Labs secured a strategic partnership with Eli Lilly and Novartis, potentially generating milestone payments of up to $3 billion for access to AI models.
Hassavis told the New York Times that the isomorphic lab didn't need capital, but the additional funding would help the department hire top research scientists.
In their work at Alphafold, Hassabis and Deepmind researcher John Jumper was one of three scientists who won the Nobel Prize in chemistry in 2024.